Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620333 | 1.00 | KDM4E (0.71) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| Water SCHEMBL7614858 | 0.98 | KDM4E (0.69) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| Methane SCHEMBL2342916 | 0.98 | KDM4E (0.69) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL5692314 | 0.85 | PARP1 (0.51) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL5698321 | 0.85 | KDM4E (0.67) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL5707628 | 0.85 | POLB (0.56) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL690246 | 0.85 | KDM4E (0.53) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL4270045 | 0.85 | KDM4E (0.67) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL1499127 | 0.85 | AGTR1 (0.60) | KDM4EAGTR1RAB9AALDH1A1HPGD | |
| SCHEMBL1170114 | 0.83 | ALDH1A1 (0.67) | KDM4EAGTR1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604697-B1 | Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer | UNIV TOKYO AGRICULTURE & TECHNOLOGY TLO CO LTD (JP) | 2015-07-01 | — | — | EP | claimed |
| EP-2604697-A1 | Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer | Tokyo University of Agriculture and Technology TLO (JP) | 2013-06-19 | — | — | EP | claimed |
| CN-101142214-B | Ocaperidone salts and pharmaceutical compositions containing the same | JANSSEN PHARMACEUTICA NV | 2011-02-23 | — | — | CN | claimed |
| EP-1888577-B1 | OCAPERIDONE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-12 | — | — | EP | claimed |
| US-20080200479-A1 | Ocaperidone Salts and Pharmaceutical Compositions Containing the Same | NEURO3D S.A. (FR) | 2008-08-21 | — | — | US | claimed |
| CN-101142214-A | Ocaperidone salts and pharmaceutical compositions containing the same | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-12 | — | — | CN | claimed |
| EP-1888577-A1 | OCAPERIDONE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-20 | — | — | EP | claimed |
| WO-2006090285-A1 | OCAPERIDONE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | claimed |
| WO-2000062771-A1 | USES OF PHENYLGLYCINE DERIVATIVES | THE UAB RESEARCH FOUNDATION (US) | 2000-10-26 | — | — | WO | claimed |
| US-20260085042-A1 | METHOD FOR PREPARING INDIGO OR A SUBSTITUTED DERIVATIVE THEREOF | PILI (FR) | 2026-03-26 | — | — | US | disclosed |
| US-20260085042-A1 | METHOD FOR PREPARING INDIGO OR A SUBSTITUTED DERIVATIVE THEREOF | PILI (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-3459441-B1 | SLOW INTRAVENTRICULAR DELIVERY | GENZYME CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4540322-A1 | METHOD FOR PREPARING INDIGO OR A SUBSTITUTED DERIVATIVE THEREOF | PILI (FR) | 2025-04-23 | — | — | EP | disclosed |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-4305858-A | Process for the preparation of stable ionic dispersions of polyisocyanate-polyaddition products in hydroxyl containing compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-15 | — | — | US | disclosed |
| US-4197219-A | Aqueous polyurethane-phenolic-formaldehyde resin emulsions for use as adhesives, primers and surface coatings | LORD CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| US-4184990-A | Process for the preparation of stable dispersions of polyisocyanate-polyaddition products in a hydroxyl containing compound as dispersing agent | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-22 | — | — | US | disclosed |
| US-4147680-A | Production of polyurethane resins using as active hydrogen material a stable dispersion of ionic polyisocyanate-polyaddition products in hydroxyl containing compounds as a dispersing agent | BAYER AKTIENGESELLSCHAFT (DE) | 1979-04-03 | — | — | US | disclosed |
| US-4092275-A | Polyurethane resins prepared from active hydrogen containing material which is a dispersion of polyisocyanate-polyaddition products in hydroxyl containing compounds as dispersing agents | BAYER AKTIENGESELLSCHAFT (DT) | 1978-05-30 | — | — | US | disclosed |
| US-3970601-A | COATINGS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085042-A1 | METHOD FOR PREPARING INDIGO OR A SUBSTITUTED DERIVATIVE THEREOF | TDO2, IDH2, IDH3A | KDM4E 3070/4885AGTR1 1073/4885RAB9A 2450/4885 |
| US-20080200479-A1 | Ocaperidone Salts and Pharmaceutical Compositions Containing the Same | OTC, PMP22, OLA1 | KDM4E 4254/4885AGTR1 862/4885RAB9A 3401/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | KDM4E 2426/4885AGTR1 638/4885RAB9A 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.